ContraVir Pharmaceuticals : Corporate Investor Deck 1.8 MB

Corporate Presentation ● January 2019

NASDAQ: CTRV

Forward-Looking

Statements

This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such statements are only predictions and our actual results may differ materially from those anticipated in these forward-looking statements.

We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Factors that may cause such differences include, but are not limited to, those discussed under Risk Factors in our periodic reports filed with the Securities and Exchange Commission, including the uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate safety and efficacy in larger-scale clinical trials, the risk that we will not obtain approval to market our products, the risks associated with dependence upon key personnel and the need for additional financing. We do not assume any obligation to update forward-looking statements as circumstances change.

This presentation does not constitute an offer or invitation for the sale or purchase of securities or to engage in any other transaction with ContraVir or its affiliates. The information in this presentation is not targeted at the residents of any particular country or jurisdiction and is not intended for distribution to, or use by, any person in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.

Snapshot

A Liver Disease Company

Committed to developing therapeutic drugs for liver disease arising from chronic viral infection (HBV, HCV, HDV) and NASH (non-alcoholic steatohepatitis)

"…Nearly 45% of all deaths in the developed world are attributed to some type of chronic fibroproliferative disease. Therefore, the demand for antifibrotic drugs that are both safe and effective is likely to be enormous..."

- J Clin Invest. 2007 Mar;117(3):524-9. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases.

Wynn TA

Immunopathogenesis Section, National Institute of Allergy and Infectious

Diseases, NIH, USA

Corporate Overview

Products

CRV431: Novel, high-potency, cyclophilin inhibitor that targets multiple stages of liver disease

• • Anti-fibrotic, anti-viral, and anti-cancer properties (pleiotropic)

• • Strong preclinical proof of concept

• • Strong safety profile in preclinical and Phase 1 clinical studies

• • Orally active, once daily

• • Robust IP

• • Built upon 30 years experience in this very specific field of chemistry

TXL™: Novel, liver-targeting, lipid conjugate of tenofovir for chronic hepatitis B virus infection

• • Phase 3-ready, 505(b)2 pathway

• • Tenofovir (TDF), WHO Model List of Essential Medicines, 20th edition, March 2017

• • Available for licensing out

Liver Disease

Targeting Common Pathways to End-Stage Liver Disease

INJURY/STEATOSISINFLAMMATIONFIBROSISCIRRHOSIS/CANCER

NAFLD/ NASHAlcoholCell injury/death

Stellate cell activation

Viral Hepatitis (HBV/HCV/HDV)

Inflammatory cell infiltration/activation

Collagen deposition (scarring)

Cellular transformation and metastasis

CRV431 demonstrates anti-viral, anti-fibrotic, and anti-cancer activities